Telo Genomics Advances Blood-Based MRD Testing in Myeloma with New Study and CAP Accreditation

Telo Genomics Corp ( (TSE:TELO) ) has issued an announcement.

Telo Genomics Corp. has launched a retrospective clinical study with hematologists at the National and Kapodistrian University of Athens to advance next‑generation minimal residual disease risk stratification in multiple myeloma. The trial will analyze baseline blood samples from patients treated with standard care and known two‑year outcomes, aiming to compare relapsed and remission cases.

The study’s goals are to analytically validate Telo Genomics’ ability to detect circulating myeloma cells with sensitivity comparable to leading Euroflow methods and to build a relapse risk scoring model based on 3D telomere profiling. By focusing on biologically driven risk indicators via a simple blood draw, the company seeks to offer clinicians a less invasive, more informative tool for monitoring remission, guiding therapy, and potentially reducing repeated bone marrow biopsies.

Telo Genomics expects to report study results in summer 2026 and to initiate up to two additional clinical trials later this year as it moves toward commercializing its cancer diagnostic platform. In parallel, the company has renewed CAP accreditation for its Toronto laboratory, strengthening quality credentials and infrastructure needed to support ongoing clinical studies and eventual market deployment of its MRD-focused technology.

These developments reinforce Telo Genomics’ ambition to secure a differentiated position in the expanding MRD testing market by integrating high‑sensitivity detection with biologically informed risk stratification. For clinicians and patients, the approach could reshape how multiple myeloma remission is monitored over time and improve the precision of treatment decisions and relapse risk assessment.

Spark’s Take on TELO Stock

According to Spark, TipRanks’ AI Analyst, TELO is a Neutral.

The score is primarily held down by weak financial performance (no revenue, persistent losses, negative free cash flow, and negative equity), which raises funding and dilution risk. Technical indicators are moderately supportive with price above key moving averages and positive MACD, but valuation remains unattractive/uncertain due to negative earnings and no dividend yield data.

To see Spark’s full report on TELO stock, click here.

More about Telo Genomics Corp

Telo Genomics Corp. is a biotechnology company focused on developing diagnostic and prognostic tests for human diseases using 3D analysis of telomeres, the protective ends of chromosomes. Its blood-based cancer platform targets the rapidly expanding minimal residual disease market, aiming to complement or reduce reliance on invasive bone-marrow-based methods in oncology care.

The company’s technology has been supported by more than 190 peer‑reviewed publications and over 30 clinical studies involving more than 3,000 patients across multiple cancers and Alzheimer’s disease. Telo Genomics operates a CAP-accredited laboratory in Toronto, positioning its platform for broader clinical adoption and integration into routine diagnostic workflows.

Average Trading Volume: 78,698

Technical Sentiment Signal: Sell

Current Market Cap: C$6.53M

For a thorough assessment of TELO stock, go to TipRanks’ Stock Analysis page.